Table 2. Sensitivity, specificity and reducible biopsies for different PSA, PSAD, F/T ratio and PSATZ values in 656 patients.

	Number of biopsies	Number of cancer	Sensitivity	Specificity	Positive predictive value	Negative predictive value	Reducible biopsies
PSA (ng/mL) greater than
3.0	656	172	1.000	0.017	0.265	1.000	1.22%
4.0	567	168	0.977	0.176	0.265	0.955	13.5%
5.0	523	154	0.895	0.238	0.294	0.865	20.2%
6.0	406	128	0.744	0.426	0.315	0.824	38.1%
7.0	301	118	0.686	0.622	0.392	0.848	54.1%
8.0	179	76	0.442	0.787	0.425	0.799	72.7%
9.0	74	40	0.233	0.930	0.541	0.773	88.7%
F/T ratio less than
0.10	82	74	0.430	0.983	0.902	0.829	87.5%
0.12	146	101	0.587	0.907	0.692	0.861	77.7%
0.14	237	121	0.703	0.760	0.511	0.878	63.8%
0.15	275	135	0.785	0.711	0.491	0.903	58.0%
0.18	303	145	0.843	0.674	0.479	0.924	53.8%
0.20	367	149	0.866	0.550	0.406	0.920	44.0%
0.22	384	155	0.901	0.527	0.404	0.938	41.4%
0.25	472	161	0.936	0.357	0.341	0.940	28.0%
0.31	603	172	1.000	0.110	0.285	1.000	8.0%
PSAD (ng/mL per mL) greater than
0.10	603	172	1.000	0.110	0.285	1.000	8.0%
0.11	570	169	0.983	0.171	0.296	0.965	13.1%
0.13	479	165	0.959	0.351	0.344	0.960	26.9%
0.15	397	158	0.919	0.506	0.398	0.946	39.4%
0.17	336	138	0.802	0.591	0.411	0.894	48.7%
0.18	309	125	0.727	0.620	0.405	0.865	52.9%
0.20	214	124	0.721	0.814	0.579	0.891	67.3%
0.22	161	91	0.529	0.855	0.565	0.836	75.4%
PSATZ (ng/mL per mL) greater than:
0.15	599	172	1.000	0.118	0.287	1.000	8.7%
0.22	494	172	1.000	0.334	0.348	1.000	24.7%
0.25	452	162	0.942	0.401	0.358	0.951	31.1%
0.30	340	151	0.878	0.610	0.444	0.934	48.1%
0.33	286	138	0.802	0.694	0.483	0.908	56.4%
0.35	262	131	0.762	0.729	0.500	0.896	60.0%
0.37	243	128	0.744	0.762	0.527	0.893	62.9%
0.40	230	128	0.744	0.789	0.557	0.897	64.9%
0.46	195	107	0.622	0.818	0.549	0.859	70.2%
0.55	148	94	0.547	0.888	0.635	0.846	77.4%

F/T ratio = free-to-total PSA ratio; PSA = prostate-specific antigen; PSAD = PSA density; PSATZ = PSA density of the transition zone